AstraZeneca — Pharmaceutical Intelligence | Humanexa Signals

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.

Recent signals(81)

FDA Accepts Supplemental NDA for Brilinta (Ticagrelor) by AstraZeneca

Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy

FDA Acceptance of Supplemental NDA for CRESTOR by AstraZeneca

FDA Submission Update for Breztri Aerosphere by AstraZeneca

FDA Acceptance of SYMBICORT AEROSPHERE Supplement by AstraZeneca

Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer

FDA Accepts Application for SAPHNELO (Anifrolimab-FNIA) by AstraZeneca

AstraZeneca's Study on AZD6234 and AZD9550 Impact on Oral Contraceptive Pharmacokinetics

AstraZeneca's GEMINI-PeriOp GC Study Targets Locally Advanced Gastroesophageal Adenocarcinoma

Ultomiris Phase III trial fails to meet primary endpoint in HSCT-TMA

Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers

AstraZeneca's EPLONTERSEN SODIUM Autoinjector Receives AP Status from FDA

AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea

AstraZeneca Initiates Phase 1b/2 Trial of AZD0120 for Relapsed/Refractory Multiple Myeloma

Etcamah Approved in EU for 1st-Line Advanced ER+ Breast Cancer

FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

FDA Approves Supplemental Application for Farxiga (Dapagliflozin)

AstraZeneca Launches AI Study for Lung Cancer Risk Stratification

AstraZeneca Initiates Phase I/II Study of AZD4512 in B-cell Non-Hodgkin Lymphoma

FDA Accepts Supplement for IMFINZI (Durvalumab) by AstraZeneca

AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

FDA Accepts Supplemental Application for KOSELUGO (Selumetinib)

AstraZeneca's AZD4954 Study Evaluates Safety and Pharmacokinetics in Healthy Adults

AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated

FDA Approves BAXFENDY (BAXDROSTAT) by AstraZeneca

AstraZeneca's Study on Durvalumab and Tremelimumab in HCC with TACE

AstraZeneca's AZD5004 Study Evaluates Drug Interaction with Mitiglinide and Pioglitazone

AstraZeneca's Study on MET Concordance in Treatment-Naïve NSCLC

FDA Accepts Supplemental Application for Fasenra (Benralizumab) by AstraZeneca

AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany

AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer

FDA Approves Supplemental Application for BRILINTA (Ticagrelor)

AstraZeneca's Rilvegostomig Study Targets Advanced Solid Tumors with Subcutaneous Administration

AstraZeneca Evaluates Surovatamig for CLL/SLL Consolidation Therapy

AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial

AstraZeneca's Anifrolumab Study for Systemic Lupus Erythematosus Underway

AstraZeneca Investigates Safety of Ondexxya IV Injection in Real-World Use

FDA Approves Supplemental Application for CRESTOR (Rosuvastatin Calcium)

AstraZeneca's Phase III Trial of Baxdrostat in Primary Aldosteronism Underway

FDA Approves Supplemental Application for Breztri Aerosphere

FDA Accepts Supplemental Application for SYMBICORT AEROSPHERE

FDA Accepts BLA for Anifrolumab by AstraZeneca

AstraZeneca initiates Phase I/II trial of AZD9829 for CD123+ hematological malignancies

AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents

FDA Accepts Supplemental Application for WAINUA Autoinjector by AstraZeneca

Enhertu Secures EU Approval as First Tumour Agnostic HER2 Therapy

Datroway recommended for EU approval as 1st-line treatment for TNBC

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

Trial Compares Rivaroxaban and Ticagrelor Against Clopidogrel for Stroke Prevention

AstraZeneca initiates Phase 3 extension study for Tozorakimab in COPD patients

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM

Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit

AstraZeneca's Capivasertib Receives AP Status from FDA

Phase Ⅲ Trial of Rilvegostomig in HER2-positive Gastric Cancer Initiated by AstraZeneca

FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer

Pentoxifylline and α-Tocopherol Study for RILI in Stage III NSCLC Patients

AstraZeneca Leads Study on DLBCL Treatment Patterns in MEA Region

FDA Acceptance of NDA for Capivasertib by AstraZeneca

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers

FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts

Saphnelo Self-Administration Approved in the US for SLE Treatment

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU